CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to understand how metastatic colorectal cancer develops from primary tumors by analyzing the immune system's role in cancer progression. It combines evolutionary analysis and high-throughput technologies to quantify immune responses and their impact on the ability of cancer cells to spread.
Colorectal cancer is the second most common cancer in Europe, and although screening has drastically increased survival, a fraction of patients still develops metastatic disease.
These patients have a 5-year survival rate of 14% compared to 70% for those non-metastatic (SEER 18).
For the majority of cases, the primary tumour is successfully resected, but disease relapse arises due to undetectable metastases.
How metastatic clones arise within the primary tumor and adapt to their microenvironment…
INSTITUTE OF CANCER RESEARCH: THE ROYAL CANCER HOSPITAL LBG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
